Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases

Journal of Surgical Oncology

Volumn 106, Issue 7, 2012, Pages 892-897

  Van Der Pool, Anne E M ^a,b   Marsman, Hendrick A ^b   Verheij, Joanne ^a   Ten Kate, Fibo J ^b   Eggermont, Alexander M M ^a,c   Ijzermans, Jan N M ^a   Verhoef, Cornelis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

bevacizumab; colorectal liver metastases; liver injury; oxaliplatin; sinusoidal dilatation

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL LIVER METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84868342910     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23142     Document Type: Article

References (31)

1. Allen PJ, Kemeny N, Jarnagin W, et al.: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7: 109-115 (discussion 16-17).
2. Verhoef C, van der Pool AEM, Nuyttens JJ, et al.: The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 2009; 52: 23-30.
3. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
4. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
5. Aloia T, Sebagh M, Plasse M, et al.: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.
6. Rubbia-Brandt L, Audard V, Sartoretti P, et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
8. Ribero D, Wang H, Donadon M, et al.: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based hemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-2767.
9. Donahower B, McCullough SS, Kurten R, et al.: Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity. Am J Physiol Gastrointest Liver Physiol 2006; 291: 102-109.
10. Redaelli CA, Semela D, Carrick FE, et al.: Effect of vascular endothelial factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004; 40: 305-312.
11. Fernando NH, Hurwitz HI:, Targeted therapy of colorectal cancer: Clinical experience with bevacizumab. Oncologist 2004; 9: 11-18.
12. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
13. Vauthey JN, Chaoui A, Do KA, et al.: Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery 2000; 127: 512-519.
14. Karoui M, Penna C, Amin-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
15. Welsh FK, Tilney HS, Tekkis PP, et al.: Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-1042.
16. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016.
17. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
18. Couinaud C:, Liver anatomy: Portal (and suprahepatic) or biliary segmentation. Dig Surg 1999; 16: 459-467.
19. Dindo D, Demartines N, Clavien PA:, Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
20. Kleiner DE, Brunt EM, Van Natta M, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2005; 41: 1313-1321.
21. Pawlik TM, Olino K, Gleisner AL, et al.: Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868.
22. Scoggins CR, Campbell ML, Landry CS, et al.: Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009; 16: 35-41.
23. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
24. Chun YS, Laurent A, Maru D, et al.: Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009; 10: 278-286.
25. Nakano H, Oussoultzoglou E, Rosso E, et al.: Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-124.
26. Zorzi D, Chun YS, Madoff DC, et al.: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008; 15: 765-772.
27. Kesmodel SB, Ellis LM, Lin E, et al.: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260.
28. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007; 14: 759-765.
29. Reddy SK, Morse MA, Hurwitz HI, et al.: Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.
30. Gruenberger B, Tamandl D, Schueller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
31. Klinger M, Eipeldauer S, Hacker S, et al.: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35: 515-520.